Connect with us
Prague Gaming & TECH Summit 2025 (25-26 March)

Blockchain

Industry Leader Novozymes OneHealth’s White Paper on Helicobacter Pylori Research was Officially Released

Published

on

Shanghai, China–(Newsfile Corp. – May 30, 2022) – On May 28, the White Paper on Helicobacter Pylori research by OneHealth, an industry leader, was officially released. In recent years, as a human pathogen with nearly half of the global infection rate, the treatment research of Helicobacter Pylori has attracted much attention. OneHealth (the Human Health Department of Novozymes Group) and Follow Your Gut Research Institute jointly released the “White Paper on Pylopass™ Lactobacillus Reuteri DSM 17648 and Helicobacter Pylori” (hereinafter referred to as the “White Paper”). This is the first scientific report on Helicobacter Pylori research led by enterprises in the industry, striving to explore and interpret the key gist and effective treatment methods of Helicobacter Pylori clinical research, and providing theoretical support for clinical treatment of Helicobacter Pylori in China.

Industry Leader Novozymes OneHealth’s White Paper on Helicobacter Pylori Research was Officially Released

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/8071/125473_0087644af4d2b9c9_001full.jpg

According to the “White Paper”, chronic infection of Helicobacter Pylori was listed as a clear carcinogen in the 15th edition of Carcinogen Report released by the US Department of Health and Human Services in December 2021. 

Advertisement

In order to further help the development of health industry and effectively reduce the disease burden of Helicobacter Pylori infection and the risk of gastric cancer in China, OneHealth made full use of Novozymes Group’s scientific research strength and technical reserves, focused on the research and clinical trials of Helicobacter Pylori, and successfully completed the “White Paper”.

In the long run, the value contribution of the “White Paper” is concentrated in three aspects: 

  • It scientifically demonstrates the infection rate of Helicobacter Pylori in the world and China, deeply analyzes the research literature of Helicobacter Pylori in China, and clarifies the infection rate, annual recovery rate and annual recovery rate by region, population and age; 
  • The authority shared the prevention, control and treatment methods of Helicobacter Pylori, integrated and analyzed the consensus of the top ten Helicobacter Pylori at home and abroad, and authoritative doctors interpreted the treatment methods;
  • The key to clinical research of Helicobacter Pylori, that is, the existing scientific evidence of Pylopass™ (Lactobacillus Reuteri DSM 17648) used in the treatment of Helicobacter Pylori, was deeply interpreted, and its clinical research and application were discussed from the perspective of evidence-based.

About Novozymes OneHealth

As a human health business brand owned by Novozymes, OneHealth has built an elite microbial R&D team around the world, reshaping the definition of a healthy and better life based on data-driven R&D direction screening, accurate health efficacy verification, rigorous scientific research attitude, high-standard in vitro trials and gold-standard clinical trials.

Company Name: Novozymes Yikang Biotechnology (Shanghai) Co., Ltd.
Website: https://novozymesonehealth.com/zh/
Email Address: [email protected]

Contact: Wang Jinxin
Telephone: 18017066245

Advertisement

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/125473

Newsfile is a customer-focused newswire team that delivers press releases and corporate announcements to the global financial community. Approved by all stock exchanges, Newsfile offers broad access to media, analysts, investors and market participants. With agile services, proactive customer care and affordable pricing; Newsfile makes it easy for companies to tell their story to the audiences they need to reach.

Blockchain

Bybit Receives Georgian VASP License, Strengthening Global Regulatory Presence

Published

on

bybit-receives-georgian-vasp-license,-strengthening-global-regulatory-presence
Continue Reading

Blockchain

Accredited Solutions, Inc. Announces Strategic Acquisition of GlobeTopper, a $37M Revenue Platform Acquisition to Anchor Fintech Strategy

Published

on

Continue Reading

Blockchain

DIGZAX Enhances Collaborative Security System, Pioneering New Heights in Cryptocurrency Trading

Published

on

digzax-enhances-collaborative-security-system,-pioneering-new-heights-in-cryptocurrency-trading

DIGZAX

Continue Reading
Advertisement
 title=
Advertisement

Latest News

Recent Listings

  • Global Payout, Inc.

    Since the Company’s inception in 2009, Global Payout, Inc. has been a leading provider of compreh...

  • MTrac Tech Corp.

    MTrac Tech Corporation, a Nevada Corporation, is a privately held, wholly owned subsidiary of Glo...

  • Net1

    Net1 is a leading provider of transaction processing services, financial inclusion products ...

  • uBUCK Technologies SEZC

    Based in Georgetown, Cayman Islands, uBUCK Tech is a fintech enterprise that specializes in digit...

  • LiteLink Technologies Inc.

      LiteLink is a major player in developing world-class enterprise platforms that utilize ar...

  • Good Gamer Corp.

      Good Gamer Corp. is a privately-held technology company focusing on gamers and streamers....

  • BitPay

      Founded in 2011, BitPay pioneered blockchain payment processing with the mission of trans...

  • About Net1

      Net1 is a leading provider of transaction processing services, financial inclusion produc...

  • Blockchain Foundry Inc.

    Headquartered in Toronto, Canada, Blockchain Foundry (CSE:BCFN)(FWB:8BF)(OTC:BLFDF) is a global b...

  • Sixgill

    Sixgill provides a full suite of universal data automation and authenticity products and services...

Trending on TBE